Sale

Allergy Immunotherapy Market

Global Allergy Immunotherapy Market Share, Size, Analysis, Report: By Treatment Type: Subcutaneous Immunotherapy (SCIT), Specific Immunotherapy (SIT), Sublingual Immunotherapy (SLIT); By Allergan Type: Pollen Allergies, Food Allergies, Others; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Allergy Immunotherapy Market Outlook

The global allergy immunotherapy market size attained a value of USD 2.24 billion in 2023 driven highly by increase in prevalence of allergic diseases. The market is anticipated to grow at a CAGR of 9.6% during the forecast period of 2024-2032 to attain a value of USD 5.10 billion by 2032.

 

allergy-immunotherapy-market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Market Likely to be Driven by Increase in Prevalence of Allergic Diseases

In the USA, over 7.5% of the people eighteen years of age or above experience allergic rhinitis or hay fever. A significant percentage of children also suffers from hay fever. Allergic rhinitis affects ten to thirty percent of the population across the globe. Further, over five percent of children across the world experience some kind of food allergy. Globally, increase in prevalence of allergic diseases has continued in the industrialized world for over fifty years. Such prevalence of allergic conditions is expected to drive the global allergy immunotherapy market. Allergies can have a significant affect on health and quality of life. Allergen immunotherapy can provide long-lasting therapeutic relief to people suffering from environmental allergies. Allergen immunotherapy (also called allergy shots) refers to a type of long-term treatment that reduces symptoms for individuals experiencing allergic rhinitis, allergic asthma, conjunctivitis (eye allergy) or stinging insect allergy. Allergy shots reduce sensitivity to allergens and usually offer lasting relief from allergy symptoms even after the treatment is stopped, making it an economical and beneficial treatment approach for several people. Immunotherapy is a preventive treatment for allergic reactions to substances like grass pollens, house dust mites and bee venom; it also decreases inflammation that characterizes rhinitis and asthma.

Adults as well as children may receive allergy shots, however, the treatment is not usually suggested for children below age five. When considering allergen immunotherapy for an older adult, medical conditions including cardiac disease must be taken into consideration. Important considerations include: duration of allergy season and severity of symptoms; how well medications and environmental controls are helping allergy symptoms; the patient’s desire to avoid long-term medication use; time available for treatment; cost. Food allergies are not treated through allergy shots.

 

Allergen Immunotherapy has been Shown to Reduce Symptoms of Several Allergies

Allergy shots act like a vaccine; the body responds to injected amounts of a specific allergen, administered in gradually increasing doses, by developing immunity or tolerance to the allergen. The gradual increases of the allergen enable the immune system to become less sensitive to the substance, possibly by causing production of a “blocking” antibody which decreases the symptoms of allergy when the substance is encountered in the future. In the build-up phase, injections are administered with increasing amounts of the allergens one to two times per week; the phase may last three to six months. The maintenance phase commences once the effective dose is reached; the effective dose depends on allergen sensitivity levels and the person’s response to the build-up phase. During the maintenance phase, the duration of time between shots might become longer (two to four weeks).

Allergen immunotherapy has been shown to reduce symptoms of several allergies; it may also prevent the development of new allergies. In children, it could prevent the development of allergic disease from allergic rhinitis to asthma. The relief provided by allergen immunotherapy is expected to boost the global allergy immunotherapy market.

Indications for allergen immunotherapy include moderate-to-severe allergic rhinitis; allergic asthma; allergic conjunctivitis; allergic rhino-conjunctivitis; atopic dermatitis; immune-mediated and IgE-mediated food allergy; insect allergy that causes significant local reaction and anaphylaxis.

 

Developments in the Domain Likely to Boost Market Growth

In 2020, it was reported that researchers from the University of Tsukuba had developed a novel system that enabled the mass production of the major birch pollen allergen Bet v 1 in plant leaves in just a few days. A study published in Frontiers in Plant Science showed that their system not only produced large amounts of Bet v 1, but the purified protein was also highly reactive towards the IgE antibodies in sera from individuals with birch pollen allergy. Such developments, along with several others in the domain, are expected to boost the global allergy immunotherapy market.

 

allergy-immunotherapy-market-by-segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentation

By allergy, the market is segmented into:

  • Allergic Asthma
  • Cat Allergy
  • Allergic Rhinitis
  • Peanut Allergy
  • Others

By treatment, the market is divided into:

  • Sublingual Immunotherapy
  • Subcutaneous Immunotherapy (SCIT)
  • Specific Immunotherapy (SIT)

By distribution channel, the market is classified into:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By region, the market is segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

allergy-immunotherapy-market-by-region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global Allergy Immunotherapy market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • ASIT Biotech
  • Circassia Group PLC
  • Adamis Pharmaceuticals Corporation
  • Merck KGaA
  • Stallergenes Greer Ltd
  • Allergy Therapeutics PLC
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • Allergan Type
  • Treatment Channel
  • Distribution Channel
  • Region
Breakup by Treatment Type
  • Subcutaneous Immunotherapy (SCIT)
  • Specific Immunotherapy (SIT)
  • Sublingual Immunotherapy (SLIT)
Breakup by Allergan Type
  • Pollen Allergies
  • Food Allergies
  • Dust Mite Allergies
  • Mold Allergies
  • Animal Dander Allergies
  • Insect Venom Allergies
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Distribution Channel
  • Direct Tenders
  • Retail Sales
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • ALK-Abelló A/S
  • Allergy Therapeutics
  • Aimmune Therapeutics
  • Stallergenes Greer
  • Merck Group
  • HAL Allergy Group
  • DBV Technologies
  • Biomay AG
  • Anergis SA
  • Circassia Pharmaceuticals
  • Laboratorios LETI
  • HollisterStier Allergy

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Allergy Diseases Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Allergy Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Allergy Epidemiology (2016-2031)
    5.3    Europe Allergy Epidemiology (2016-2031)
    5.4    Asia-Pacific Allergy Epidemiology (2016-2031)
    5.5    Latin America Allergy Epidemiology (2016-2031)
    5.6    Middle East & Africa Allergy Epidemiology (2016-2031)
6    Global Allergy Immunotherapy Market Overview 
    6.1    Global Allergy Immunotherapy Market Historical Value (2017-2023)
    6.2    Global Allergy Immunotherapy Market Forecast Value (2024-2032)
7    Global Allergy Immunotherapy Market Landscape
    7.1    Global Allergy immunotherapy: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Allergy Product Landscape
        7.2.1    Analysis by Treatment Type
        7.2.2    Analysis by Allergan Type
        7.2.3    Analysis by Distribution Channel
8    Allergy Immunotherapy Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Allergy Immunotherapy Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Allergy Immunotherapy Market Segmentation
    11.1    Global Allergy Immunotherapy Market by Treatment Type
        11.1.1    Market Overview
        11.1.2    Subcutaneous Immunotherapy (SCIT)
        11.1.3    Specific Immunotherapy (SIT)
        11.1.4    Sublingual Immunotherapy (SLIT)
            11.1.4.1    Sublingual Drops
            11.1.4.2    Sublingual Tablets 
    11.2    Global Allergy Immunotherapy Market by Allergan Type
        11.2.1    Market Overview
        11.2.2    Pollen Allergies
            11.2.2.1    Grass Pollen
            11.2.2.2    Tree Pollen
            11.2.2.3    Weed Pollen
        11.2.3    Food Allergies
            11.2.3.1    Peanut Allergies
            11.2.3.2    Tree Nut Allergies
            11.2.3.3    Shellfish Allergies
            11.2.3.4    Fish Allergies
            11.2.3.5    Egg Allergies
            11.2.3.6    Milk Allergies
            11.2.3.7    Soy Allergies
            11.2.3.8    Wheat Allergies
            11.2.3.9    Others
        11.2.4    Dust Mite Allergies
        11.2.5    Mold Allergies
        11.2.6    Animal Dander Allergies
        11.2.7    Insect Venom Allergies
    11.3    Global Allergy Immunotherapy Market by Treatment Channel
        11.3.1    Market Overview
        11.3.2    Public
        11.3.3    Private
    11.4    Global Allergy Immunotherapy Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Direct Tenders
        11.4.3    Retail Sales
        11.4.4    Others
    11.5    Global Allergy Immunotherapy Market by Region
        11.5.1    Market Overview
        11.5.2    North America
        11.5.3    Europe 
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Allergy Immunotherapy Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Allergy Immunotherapy Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Allergy Immunotherapy Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Allergy Immunotherapy Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Allergy Immunotherapy Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    ALK-Abelló A/S
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Allergy Therapeutics
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Aimmune Therapeutics
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Stallergenes Greer
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Merck Group
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    HAL Allergy Group
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    DBV Technologies
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Biomay AG
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Anergis SA
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Circassia Pharmaceuticals
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Laboratorios LETI
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    HollisterStier Allergy
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
24    Allergy Immunotherapy Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market of Allergy Immunotherapy attained a value of USD 2.24 billion.

The market is anticipated to grow at a CAGR of 9.6% during the forecast period of 2024-2032 to reach a value of USD 5.10 billion by 2032.

The major drivers of the market include the climate change, standardisation of dosage, strong pipeline of immunotherapy products, and increased consumption of alcohol.

The rising prevalence of allergic disorders and increasing air pollution, both indoors and outdoors, are the key industry trends propelling the market's growth.

For some allergies, success rates have been shown to be as high as 80-90%. It is a lengthy procedure; if therapy is effective, it should be continued for three to five years after considerable improvement is seen.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major allergies studied in the market are allergic asthma, cat allergy, allergic rhinitis, and peanut allergy, among others.

Based on treatment, the market is classified into sublingual immunotherapy, subcutaneous immunotherapy (SCIT), and specific immunotherapy (SIT).

The several distribution channels of the market are retail pharmacy, hospital pharmacy, and online pharmacy.

Treatment with maintenance immunotherapy typically lasts for about 3 to 5 years. The length of allergen immunotherapy varies from person to person, since some people get long-lasting remission of their allergy symptoms, while others may experience relapse after stopping immunotherapy.

The major players in the industry are ASIT Biotech, Circassia Group PLC, Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer Ltd, and Allergy Therapeutics PLC, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER